Search |

Add/Edit My Facility

Stem Cell Engineering Core (Stem Cell)

Subscribe to this Core


cite this facility

Facility LIMS Page

iLab

Primary Contact:

Samuele Marro

0000-0002-9326-6945

Facility RRID

RRID:SCR_027503

Additional Citation Identifiers

5P30AR079200-055R01MH134319-031R21NS130319-01A15R01DA054526-041R56AG088669-01

Facility Details

The SCEC provides comprehensive services for the generation and characterization of induced pluripotent stem cells (iPSCs) from somatic sources such as blood and fibroblasts, along with long-term cryobanking. The Core also offers access to a diverse collection of well-characterized iPSC lines derived from both healthy donors and patients with various diseases, representing a range of ethnic backgrounds and sexes.

A major focus of the SCEC is gene editing in pluripotent stem cells, with extensive expertise in CRISPR-based applications—from precise point mutation knock-in (correction or introduction) to the generation of reporter lines (e.g., GFP and other fluorescent reporters) and inducible systems such as Cre-lox, dTAG, and beyond.

In addition, the Core provides guidance and support for the differentiation of iPSCs into multiple cell types, using both monolayer and 3D organoid formats, enabling downstream disease modeling and functional studies.

Funding Info

NIH - 09/20/2025 - Resource Core B - Modeling of skin disease for mechanistic analysis and therapeutic discovery

is_active:

Yes

budget_end:

08/31/2026

date_added:

09/20/2025

agency_code:

NIH

fiscal_year:

2025

project_num:

5P30AR079200-05

award_amount:

$141,235.00

budget_start:

09/01/2025

org_name:

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

org_state:

NY

org_country:

UNITED STATES

org_zipcode:

100296574

primary_duns:

078861598

abstract_text:

Summary – Resource Core B Many technical, logistical and cost barriers hinder efficient and feasible access to high-end experimental approaches in skin research. Efforts by Core B, “Modeling of skin disease for mechanistic analysis and therapeutic discovery” will systematically overcome these barriers for skin researchers by facilitating access to human skin samples, harnessing our expertise in generating and analyzing sophisticated mouse genetic and human iPSC-derived models of skin disease, and providing a streamlined interface with Core C for genomics and transcriptional analyses. In parallel, the entry barriers to skin biology and diseases research will be lowered by providing Pilot Grants to junior investigators and researchers newly entering the skin biology and diseases field, and the costs of high-end technologies will be defrayed by User Scholarships. Core B will offer users specialized technical, clinical and scientific know-how and services in advanced skin research as well as critical research infrastructure by providing A) clinical and histopathological expertise for easy retrieval of normal and diseased human skin and access to efficient multiplexed skin marker analysis for physiological and skin disease studies; B) scientific expertise and service for physiological studies of fundamental skin functions with advanced genetic mouse models and cell isolation and imaging technologies; and C) scientific expertise and service for human skin disease modeling with patient-derived iPSC technology and with CRISPR-based gene editing and expression manipulation for mechanistic analysis and therapeutic target discovery. These goals will specifically be achieved by 1) providing samples from our vast collection of archived normal and diseased human skin; 2) facilitating access to de-identified fresh human skin samples; 3) advanced multiplexed immunohistochemical imaging of marker proteins; 4) aiding in the generation of state-of-the-art genetic mouse models for skin functional studies; 5) providing training in refined isolation technologies for specific skin cell populations; 5) providing training for advanced live imaging in vitro and in vivo; 6) generating patient iPSCs and differentiating them to skin cells to model human skin disease; and 7) studying candidate skin disease genes by generating isogenic mutant and control iPSC-derived skin cells and through Cas9-based gene expression manipulation.

project_title:

Resource Core B - Modeling of skin disease for mechanistic analysis and therapeutic discovery

contact_pi_name:

RENDL, MICHAEL

total_cost:

$141,235.00

Facility Policies

Services are offerred outside of

Consulting is offerred outside of Icahn School of Medicine at Mount Sinai

Last Updated: 05/19/2025